Localization of human sarcoma with radiolabeled monoclonal antibody - a follow-up report

John A. Greager; Tzu Chieh Chao; John M. Brown; Dan G. Pavel; Micheal J. Blend; Tapas K. Das Gupta

doi:10.1007/BF01756600

Localization of human sarcoma with radiolabeled monoclonal antibody - a follow-up report

John A. Greager^*, Tzu Chieh Chao, John M. Brown, Dan G. Pavel, Micheal J. Blend, Tapas K. Das Gupta

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

1 Scopus citations

Abstract

A group of 16 sarcoma patients with suspected advanced disease were studied with a radiolabeled anti-sarcoma monoclonal antibody (mAb 19-24) in an attempt to localize tumor deposits. All 16 patients received¹²⁵I-mAb 19-24 and then had external-probe analysis and imaging performed. Confirmation of tumor deposits was done at surgery or by autopsy. Tissues were studied in surgical patients when possible and analyzed for radioactivity, and tumor-to-blood ratios ranged from 0.6 to 36.8. In conjunction with the patients previously studied, probe results had an overall sensitivity of 83.3% and an overall specificity of 100%; scintigraphic results showed an overall sensitivity of 78.9% and an overall specificity of 100%. Radiolabeled mAb 19-24 may be developed into a useful tool for clinical immunodetection of sarcoma deposits.

Original language	English
Pages (from-to)	341-345
Number of pages	5
Journal	Cancer Immunology Immunotherapy
Volume	33
Issue number	5
DOIs	https://doi.org/10.1007/BF01756600
State	Published - 09 1991
Externally published	Yes

Keywords

Human sarcoma
Radiolabeled antibody

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF01756600

Cite this

@article{bc41106a98c34e35bb0f6d590323ee09,

title = "Localization of human sarcoma with radiolabeled monoclonal antibody - a follow-up report",

abstract = "A group of 16 sarcoma patients with suspected advanced disease were studied with a radiolabeled anti-sarcoma monoclonal antibody (mAb 19-24) in an attempt to localize tumor deposits. All 16 patients received125I-mAb 19-24 and then had external-probe analysis and imaging performed. Confirmation of tumor deposits was done at surgery or by autopsy. Tissues were studied in surgical patients when possible and analyzed for radioactivity, and tumor-to-blood ratios ranged from 0.6 to 36.8. In conjunction with the patients previously studied, probe results had an overall sensitivity of 83.3% and an overall specificity of 100%; scintigraphic results showed an overall sensitivity of 78.9% and an overall specificity of 100%. Radiolabeled mAb 19-24 may be developed into a useful tool for clinical immunodetection of sarcoma deposits.",

keywords = "Human sarcoma, Radiolabeled antibody",

author = "Greager, {John A.} and Chao, {Tzu Chieh} and Brown, {John M.} and Pavel, {Dan G.} and Blend, {Micheal J.} and {Das Gupta}, {Tapas K.}",

year = "1991",

month = sep,

doi = "10.1007/BF01756600",

language = "英语",

volume = "33",

pages = "341--345",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Localization of human sarcoma with radiolabeled monoclonal antibody - a follow-up report

AU - Greager, John A.

AU - Chao, Tzu Chieh

AU - Brown, John M.

AU - Pavel, Dan G.

AU - Blend, Micheal J.

AU - Das Gupta, Tapas K.

PY - 1991/9

Y1 - 1991/9

N2 - A group of 16 sarcoma patients with suspected advanced disease were studied with a radiolabeled anti-sarcoma monoclonal antibody (mAb 19-24) in an attempt to localize tumor deposits. All 16 patients received125I-mAb 19-24 and then had external-probe analysis and imaging performed. Confirmation of tumor deposits was done at surgery or by autopsy. Tissues were studied in surgical patients when possible and analyzed for radioactivity, and tumor-to-blood ratios ranged from 0.6 to 36.8. In conjunction with the patients previously studied, probe results had an overall sensitivity of 83.3% and an overall specificity of 100%; scintigraphic results showed an overall sensitivity of 78.9% and an overall specificity of 100%. Radiolabeled mAb 19-24 may be developed into a useful tool for clinical immunodetection of sarcoma deposits.

AB - A group of 16 sarcoma patients with suspected advanced disease were studied with a radiolabeled anti-sarcoma monoclonal antibody (mAb 19-24) in an attempt to localize tumor deposits. All 16 patients received125I-mAb 19-24 and then had external-probe analysis and imaging performed. Confirmation of tumor deposits was done at surgery or by autopsy. Tissues were studied in surgical patients when possible and analyzed for radioactivity, and tumor-to-blood ratios ranged from 0.6 to 36.8. In conjunction with the patients previously studied, probe results had an overall sensitivity of 83.3% and an overall specificity of 100%; scintigraphic results showed an overall sensitivity of 78.9% and an overall specificity of 100%. Radiolabeled mAb 19-24 may be developed into a useful tool for clinical immunodetection of sarcoma deposits.

KW - Human sarcoma

KW - Radiolabeled antibody

UR - http://www.scopus.com/inward/record.url?scp=0025902333&partnerID=8YFLogxK

U2 - 10.1007/BF01756600

DO - 10.1007/BF01756600

M3 - 文章

C2 - 1868492

AN - SCOPUS:0025902333

SN - 0340-7004

VL - 33

SP - 341

EP - 345

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 5

ER -

Localization of human sarcoma with radiolabeled monoclonal antibody - a follow-up report

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this